# Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors

> **NCT00972205** · NA · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 12 (actual)

## Conditions studied

- Cervical
- Ovarian
- Lung
- Breast
- Renal

## Interventions

- **DRUG:** paclitaxel
- **DRUG:** CBT-1(Registered Trademark)
- **RADIATION:** Tc 99m sestamibi

## Key facts

- **NCT ID:** NCT00972205
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2012-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00972205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00972205, "Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00972205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*